AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00072839
Drug: teduglutide 0.05
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
Trial: NCT00072839
Drug: teduglutide 0.2 mg
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.2 mg/kg/d subcutaneously injected into thigh or abdomen
Trial: NCT00072839
Drug: Teduglutide 0.05 dose
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
Trial: NCT00072839
Drug: teduglutide 0.1 mg dose
DrugBank: Teduglutide (DB08900)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
Trial: NCT02327832
Drug: bone marrow-derived mesenchymal stem cells
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00608374
Drug: chlorambucil
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00608374
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00880919
Drug: quetiapine extended-release
RxNorm normalized name: Quetiapine Extended-Release Tablets
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
Trial: NCT00982007
Drug: Ferric Carboxymaltose (FCM)
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
Trial: NCT00982007
Drug: Ferrous Sulfate Tablets
RxNorm normalized name: Ferrous Sulfate Tablets
DrugBank: Ferrous tartrate (DB13639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg Ferrous Sulfate tablets taken orally three times a day
Trial: NCT03131375
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
Trial: NCT02941601
Drug: Necitumumab
RxNorm normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02941601
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT00914511
Drug: avanafil 200mg
RxNorm normalized name: AVANAFIL 200MG ORAL TAB
DrugBank: Avanafil (DB06237)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single dose tablet of 200mg avanafil
Trial: NCT00914511
Drug: avanafil 200mg
RxNorm normalized name: AVANAFIL 200MG ORAL TAB
DrugBank: Avanafil (DB06237)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single tablet dose of 200mg avanafil
Trial: NCT02941601
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT00335088
Drug: Moxifloxacin and Povidone Iodine vs Povidone Iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02015637
Drug: Delafloxacin
RxNorm normalized name: Delafloxacin
DrugBank: Delafloxacin (DB11943)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single dose
Trial: NCT02015637
Drug: Ceftriaxone
RxNorm normalized name: Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT02910882
Drug: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
RxNorm normalized name: PEGylated recombinant human hyaluronidase PH20
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:~Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.~PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.~Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy.
Trial: NCT02910882
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.~Dosing Schedule: Weekly, beginning Day #2, per standard regimen.
Trial: NCT01100801
Drug: TS-1 with cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01100801
Drug: TS-1 with oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01046708
Drug: micronized progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600mg in 3 separate doses per day
Trial: NCT00814502
Drug: Zolpidem CR
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
Trial: NCT03709342
Drug: CM4620-IE
RxNorm normalized name: CM4620
DrugBank: CM4620 (DB16466)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single IV infusion on Day 1 over 4 hours
Trial: NCT00705432
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
Trial: NCT03074513
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00705432
Drug: Boceprevir
RxNorm normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
Trial: NCT03920150
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be treated with 3 doses of alcoholic solution for 3 months.
Trial: NCT03920150
Drug: Vitamin D oily capsules
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be treated with 3 capsules for 3 months.
Trial: NCT03920150
Drug: Vitamin D oily capsules
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be treated with weekly capsules for an individually calculated number of weeks.
Trial: NCT02454387
Drug: ONO-4474 Part A1
RxNorm normalized name: Zygomycin A1
DrugBank: Paromomycin (DB01421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02454387
Drug: ONO-4474 Part B
RxNorm normalized name: SODIUM CHLORITE 0.0256 kg in 1 kg TOPICAL SPRAY [Chlorsan 105 Part B]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02454387
Drug: ONO-4474 Part C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02454387
Drug: ONO-4474 Part D
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers
Trial: NCT02331680
Drug: OPC-41061
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02185131
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
Trial: NCT03126591
Drug: Olaratumab
RxNorm normalized name: Olaratumab
DrugBank: Olaratumab (DB06043)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IV
Trial: NCT03126591
Drug: Pembrolizumab (KEYTRUDA®)
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT02115048
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02115048
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03107871
Drug: Valganciclovir
RxNorm normalized name: Valganciclovir
DrugBank: Valganciclovir (DB01610)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
Trial: NCT00234533
Drug: Somatropin (rDNA origin)
RxNorm normalized name: Somatropin (rDNA origin)
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
Trial: NCT01269021
Drug: mycophenolate mofetil plus lower dose of Prednisone
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MMF 1.0-1.5g/d\*6mons Prednisone 0.4-0.6 mg/kg/d
Trial: NCT01269021
Drug: Prednisone in full dose
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.8-1mg/kg/d
Trial: NCT00596466
Drug: pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: pregabalin
Trial: NCT02113904
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 6 injections (one every 15 days during 3 months)
Trial: NCT02672475
Drug: Galunisertib
RxNorm normalized name: Galunisertib
DrugBank: Galunisertib (DB11911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02672475
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00763035
Drug: Regadenoson
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit.
Trial: NCT00763035
Drug: Dobutamine
RxNorm normalized name: Dobutamine
DrugBank: Dobutamine (DB00841)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will receive dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
Trial: NCT01521975
Drug: Telbivudine, Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
Trial: NCT01314508
Drug: Increlex
RxNorm normalized name: Increlex
DrugBank: Mecasermin (DB01277)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
Trial: NCT03741530
Drug: Glibenclamide Tablets
RxNorm normalized name: glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Giving glibenclamide tablets, 1.25 mg 3 times daily, orally or through gastric tube, for 7 consecutive days after enrollment.
Trial: NCT01135251
Drug: dimiracetam
RxNorm normalized name: Dimiracetam
DrugBank: Dimiracetam (DB13018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
Trial: NCT01135251
Drug: sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
Trial: NCT04627402
Drug: Conbercept and TA
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Conbercept (DB12460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreous injection of Conbercept and TA
Trial: NCT04627402
Drug: Conbercept
RxNorm normalized name: Conbercept
DrugBank: Conbercept (DB12460)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreous injection of Conbercept
Trial: NCT00180778
Drug: Low dose steroids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02131259
Drug: Afatinib dimaleate
RxNorm normalized name: afatinib dimaleate
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 20mg - 50mg
Trial: NCT00093041
Drug: Zalutumumab
RxNorm normalized name: Zalutumumab
DrugBank: Zalutumumab (DB12202)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly infusion
Trial: NCT03982381
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Active comparator
Trial: NCT02158546
Drug: ALKS 5461
RxNorm normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Trial: NCT03982381
Drug: Dapagliflozin 10 MG
RxNorm normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental treatment
Trial: NCT01068847
Drug: 2-4 of the drugs listed below
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
Trial: NCT03869047
Drug: Dexmedetomidine +bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive combined general anesthesia and Quadratuslumborum block( transincisional ie before wound closure)with 19 mL of bupivacaine 0.20%plus 1 mic/kg of dexmedetomidine, total volume 20 ml
Trial: NCT03869047
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive combined general anesthesia and quadratus lumborum block (transincisional) with 20 ml of bupivacaine 0.20% .
Trial: NCT04467203
Drug: Fadanafil
RxNorm normalized name: Avanafil
DrugBank: Avanafil (DB06237)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Seven subjects in group A will receive treatment in the following order:~At Day 1, a single dose of Fadanafil 100mg will be administered orally after overnight fasting-\>~At Day 8, a single dose of Fadanafil 100mg will be administered orally with high fat meal;Seven subjects in group B will receive treatment in the following order:~At Day1, a single dose of Fadanafil 100mg will be administered orally with high fat meal-\> At Day 8, a single dose of Fadanafil 100mg will be administered orally after overnight fasting
Trial: NCT00860860
Drug: IMP-288 labeled with In111 and Lu177
RxNorm normalized name: Albumin, blood serum, labeled with iodine-125
DrugBank: Albumin iodinated I-125 serum (DB09429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMP-288: 100 microgram
Trial: NCT00495352
Drug: Hihg-doseNRT, Low-dose NRT, bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02057250
Drug: Sarilumab
RxNorm normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Solution Route of administration: Subcutaneous
Trial: NCT02057250
Drug: Sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dispensed according to local practice.
Trial: NCT02057250
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dispensed according to local practice.
Trial: NCT02057250
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dispensed according to local practice.
Trial: NCT03771664
Drug: SAGE-217
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as capsules.
Trial: NCT04096716
Drug: Tc-99m tilmanocept
RxNorm normalized name: TECHNETIUM TC-99M TILMANOCEPT
DrugBank: Technetium Tc-99m tilmanocept (DB09266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc-99m tilmanocept is a radioactive diagnostic agent.
Trial: NCT03583892
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One of the groups of patients was exposed to preoperative gabapentin. As the pain has a complex involvement of multiple mechanisms, multimodal analgesic techniques utilizing a number of drugs acting on different analgesic mechanisms are being used. In this case, some patients received gabapentin as a part of a multimodal analgesic technique.
Trial: NCT00694941
Drug: ONO-2506PO
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg QD / 5 years
Trial: NCT03501498
Drug: Loperamide
RxNorm normalized name: Loperamide
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alters intestinal transit time.
Trial: NCT03501498
Drug: Senna
RxNorm normalized name: Senna
DrugBank: Senna leaf (DB15889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alters intestinal transit time.
Trial: NCT02120898
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cream, generic formulation of the brand product.
Trial: NCT00831181
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU: continuous infusion via portable pump during all RT (approximately 33 days)
Trial: NCT00831181
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin: 50mg/m2 weekly dosing during RT (Day 1)
Trial: NCT03418714
Drug: Salvinorin A
RxNorm normalized name: Salvinorin A
DrugBank: Salvinorin A (DB12327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvinorin A, blinded doses
Trial: NCT01465919
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
Trial: NCT01261299
Drug: Carbon-14-labeled carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
Trial: NCT01635296
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
Trial: NCT01635296
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
Trial: NCT00783068
Drug: Lipopolysaccharide E. Coli 113:H 10:K negative
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.